{"id":2172067,"date":"2022-05-19T13:50:00","date_gmt":"2022-05-19T11:50:00","guid":{"rendered":"http:\/\/nhub.news\/?p=2172067"},"modified":"2022-05-20T03:29:34","modified_gmt":"2022-05-20T01:29:34","slug":"big-bottle-the-baby-formula-nightmare","status":"publish","type":"post","link":"http:\/\/nhub.news\/de\/2022\/05\/big-bottle-the-baby-formula-nightmare\/","title":{"rendered":"Big Bottle: The Baby Formula Nightmare"},"content":{"rendered":"<p style=\"text-align: justify;\"><b>This is a true crisis that is a long-time coming. Thank the baby formula monopoly, its partner at the Food and Drug Administration, and the Department of Agriculture.<\/b><br \/>\nWelcome to BIG, a newsletter about the politics of monopoly. If you\u2019d like to sign up, you can do so here. Or just read on\u2026 Today I\u2019m writing about the nightmarish baby formula shortage. I\u2019ll try to explain what the problem is, and how to fix it. Plus, defense attorneys for poultry executives accused of price-fixing attack Antitrust Division chief Jonathan Kanter for citing the book \u201cThe Chickenshit Club.\u201d And the random monopoly of the day, California\u2019s mystery gasoline surcharge. And now\u2026 As anyone with an infant knows, there is a major crisis in the feeding of America\u2019s babies right now, because parents in some areas can\u2019t get baby formula. A few months ago, a major producer of formula &#8211; Abbott Labs &#8211; shut down its main production facilities in Sturgis, Michigan, which had been contaminated with the bacteria Cronobacter sakazakii, killing two babies and injuring two others. Abbott provides 43% of the baby formula in the United States, under the brand names Similac, Alimentum and EleCare, so removing this amount of supply from the market is the short-term cause of the problem. (Abbott and Mead Johnson produce 80% of the formula in the U.S., and if you add in Nestle, that gets to 98% of the market.) The problem is not, however, that there isn\u2019t enough formula, so much as the consolidated distribution system creates a lot of shortages in specific states. First, it\u2019s hard to convey what a nightmare this situation is for parents, especially those whose children require special kinds of formula because of gastrointestinal issues or food allergies. \u201cThe shortage has led us to decide to put a feeding tube in our child,\u201d said one parent, who simply could not get the specialized formula her daughter needs. Baby formula is not just food, but the primary or sole nutrition for a vulnerable person in a stage of life in which very specific nutritional requirements are necessary for growth. Baby formula was created during the 19th century as we developed modern food preservation techniques. Before this remarkable innovation, baby starvation was common if a mother couldn\u2019t breastfeed her infant (which happens a lot). The invention of industrialized formula was one of those creations we take for granted, but like antibiotics and other medical and scientific advances, it was one that fundamentally changed parenthood and the family. This shortage is showing just how reliant we are on industrialized formula. The causal factor behind the crisis is poor regulation and a consolidated and brittle supply chain. Imports from Europe are often prohibited, even if there were excess productive capacity elsewhere. I spent a bit of time calling around to people who work in formula, and the industry is basically on a war footing. Everyone is panicking, because the situation is, in short, a nightmare. I\u2019m going to try and lay out the situation, and explain the market structure. There are two basic mechanisms that have created a concentrated and brittle market. The first is that regulators are tough on newcomers, but soft on incumbents. And the second is that the Federal government buys more than half of the baby formula in the market, and under the guise of competitive bidding, it in fact hands out monopoly licenses for individual states. That makes it impossible to get newcomers of any scale into the market, along with the more resiliency that such competition brings. It also makes it hard to address shortages in one state with extra formula from elsewhere. But first, let\u2019s start by following the money. The simplest way to understand why there\u2019s a shortage is to look at the incentives for the CEO of Abbott Labs. Here\u2019s a Reuters report coming out of the company\u2019s investor call in April, after the factory shutdown was underway. Keep in mind, the executives on this call are the people responsible for managing this vital resource, and here\u2019s how seriously they took the problem. Not a single Wall Street analyst asked about the recall. Why? In some ways, it\u2019s because it doesn\u2019t matter that much to the bottom line. Abbott Labs is a diversified medical devices and health care company, and its nutritional segment is a relatively small part part of its business. But also, if you need baby formula, which is highly regulated by the Food and Drug Administration, and distributed by a monopoly-friendly system run by the Department of Agriculture, where else are you gonna go? And that\u2019s the problem. Baby formula is a shared monopoly, and we are at the mercy of Abbott Labs, Read Johnson, and Nestle. And their execs know it. So how does this shared monopoly work? Let\u2019s start with the regulators. Subscribe now<br \/> Entering the baby formula market is a difficult process, and takes years of work. For instance, Bobbie, which makes European-style formula with a contract manufacturer, is the first firm to come into the market in five years. Bobbie is also a direct to consumer niche firm, so it doesn\u2019t have the scale to address the market dislocation at hand. It was a rough road getting started; the firm faced a recall and a shut down purely for manufacturing in Germany, and it had to go through millions of dollars of capital and a steep learning curve to get its product accepted by the FDA. The reason for regulatory hurdles seems good, on the surface. Manufacturing formula is very specific, it\u2019s not like a snack bar, it fits in somewhere between medication and food in the regulatory spectrum. Congress put extremely detailed instructions in the Infant Formula Act of 1980. To get a product approved, an entrant needs protein efficiency studies, thousands of quality tests from raw ingredients to the end product, nutritional tests to make sure it is suitable for infants, and approvals for new suppliers. There are specialized forms of formula for babies with different conditions. Naturally, starting a new formula firm takes a massive amount of time, patience, and capital. And that\u2019s if you just want to make a product and can even find a contract manufacturer to produce it for you. There is just one contract manufacturer of baby formula in the U.S. &#8211; Perrigo Nutritionals, and it requires a large initial order volume, which adds a hurdle to new potential firms. What about new factories? Earlier this year, a nutrition company ByHeart became just the fourth infant formula brand to have its own factory, something no one else had done in fifteen years. Certifying a factory for infant formula, like making a new product, is difficult and expensive. Is this expense necessary? Not entirely. The institutional risk tolerance of the FDA is extraordinarily low. FDA officials see themselves as an elite priesthood, pursuing excellence merely by dint of being at the FDA. From this perspective, there is zero incentive to let new players into the baby formula market when, in their view, there are already excellent quality companies serving the market, such as Abbott Labs, Mead Johnson, and Nestle. It\u2019s true that baby formula is overpriced in the U.S., costing about twice as much as it does throughout much of Europe. But to an FDA official, price is incidental. The thinking goes, who wants to be the official that accidentally lets a reckless entrepreneur poison a bunch of babies, just so that there\u2019s some competition in a market that is already delivering good products? When there is no problem at hand, there is no reason to allow innovation in the industry, or additional capacity. The problem, of course, is that the FDA is harsh to newcomers, but deferential to incumbents. According to Healthy Babies Bright Futures, baby formula made by the big guys in the U.S. is full of dangerous brain-altering heavy metals. HBBF tested thirteen different baby formulas, and every single one had \u201cdetectable levels of arsenic, cadmium, lead and\/or mercury,\u201d which are all considered to be neurotoxic, interfering with brain development and \u201ccausing permanent IQ reductions in children.\u201d<br \/> Moreover, FDA inspections of Abbott plants are obviously a disaster. Abbott had old and dirty equipment making formula, falsified records, deceived regulators, had bad product tracing, and did not fix problems after discovery. FDA inspectors noticed problems with the plant in September, but ignored them. Then, a whistleblower told the FDA of these problems in October, but regulators didn\u2019t even bother to interview him\/her until December. Moe Tkacik, in a viral Twitter thread, persuasively laid out parallels to the Boeing\/FAA disaster. So that\u2019s the regulatory problem. Then there\u2019s the market structure, which creates a lumpy distribution system when there\u2019s a shortage. The biggest buyer of infant formula in the U.S. is WIC, or the Special Supplemental Nutrition Program for Women, Infants, and Children, which is run by the Department of Agriculture. Roughly half of women get formula from WIC. Rather than food stamps, which is a set amount of cash that can be used for most products, most states only allow women to buy formula from one company, though each company offers a bunch of different brands. To save money, the government requires states to hold auctions to get the lowest price for formula. The problem is, state agencies use a complex rebating system to give the contract for the entire state to one manufacturer, and that contract can only be changed once every four years. Here\u2019s the USDA explaining the program. This rebate system distorts the entire market in a state, because it\u2019s just not worth having alternative formulas on a retail shelf if half of the buyers simply cannot purchase those formulas. As a result, the market tips to the WIC supplier, and that supplier raises prices on non-WIC recipients, and does so by between 26-35%. Here\u2019s what happened to the baby formula market in California when the WIC contract changed hands. This whole scheme, done under the guise of welfare, is essentially a transfer of wealth from the middle class to the poor, done by enriching the baby formula cartel. The monopoly friendly program design was peddled by the anti-poverty group the Center for Budget and Policy Priorities, which is both on the center-left of the political spectrum and aligned with Wall Street. This brings us back to the shortage. According to Truthout, Abbott is the monopoly provider of formula for 34 states, seven Indian tribal organizations, four territories and Washington, D.C. So that\u2019s where we\u2019d expect the shortages to be focused. Because of the design of the program, it\u2019s not particularly easy to move different kinds of formula to WIC recipients. And that, perhaps more than any actual national shortage, is the problem. Here\u2019s the Wall Street Journal today. \u201cThe FDA said overall the nation\u2019s infant formula manufacturers are making enough to meet demand even w\/out Abbott\u2019s main factory online. The industry sold more formula in April than it did the month before the recall, the FDA said.&#8220; The White House echoed these claims, asserting that \u201cmore infant formula has been produced in the last four weeks than in the four weeks preceding the recall.\u201d<br \/> There\u2019s a well-known black market in formula, which speaks to the dysfunction of the distribution system. The shortages are concentrated in certain areas even if nationally there might be enough to get by. According to Heather Bottemiller Evich, there are just \u201c6 states that had baby formula out-of-stock rates higher than 50 percent: Iowa, South Dakota, and North Dakota were 50-51%. Missouri was 52%. Texas was 53% and Tennessee was 54%.\u201d But nationally, it\u2019s not so bad. In some ways, the problem is that there\u2019s baby formula, but it\u2019s not in the right place (though the Sturgis factory was a monopoly producer of lots of specialized formulas, so the actual shortage itself is a huge problem). The simplest solution here is to get aggressive and capable leadership around logistics, and then move the formula where it needs to go. We\u2019ll have to open up imports temporarily, and move supply around the country while allowing WIC recipients to buy non-contract brands. I suspect at some point the Biden administration will get their hands on the situation, and fix it. There will be Congressional hearings, and Abbott\u2019s CEO will get yelled at. Longer-term, I hope there will be consequences. First, we need to explore forcing Abbott to break off its nutritional division from the rest of the firm, since it\u2019s fairly obvious that there\u2019s little corporate focus on making sure the baby formula division is run well. Conglomerates are usually inefficient. Second, Congress should really restructure the WIC program so that the auctions don\u2019t create monopolies, and lumpy distribution patterns that induce regional shortages. Finally, the FDA needs wholesale reform, since this kind of crisis seems to happen a lot. I mean, the relationship between the FDA and Abbott Labs was also behind the rapid Covid testing scandal, where FDA official Tim Stenzel &#8211; who had worked at Abbott &#8211; then approved Abbott as one of two firms to make those tests, and blocked all other entrants. That\u2019s why rapid Covid tests were both in shortage and much more expensive in the U.S. than they are in Europe. The FDA needs to be broken up so that its drugs and food divisions are separate, and it needs to take its mandate seriously for a resilient supply chain. In some ways, this baby formula crisis is the same problem as United having passenger David Dao being beaten up in 2017 and removed from the plane, to public horror and Congressional rage. United\u2019s stock went up after the incident. Or it\u2019s like nurses wearing garbage bags at the beginning of the pandemic because of our dependence on China, and the sad reality that policymakers in the last two years have refused to stop sourcing from China. Hopefully, these kinds of failures, and the public rage, are laying the groundwork for wholesale reform of our government. At every level of policymaking, we have a systemic bias against people who focus on making things, in favor of well-branded monopolists and cloistered regulators who are obsessed with fanciness instead of actual critical thinking. And that\u2019s no way to run a democracy. A few weeks ago, DOJ Antitrust chief Jonathan Kanter publicly said that his division would continue to press for criminal charges for antitrust violations. Kanter referenced the \u2018Chickenshit Club,\u2019 a book about how prosecutors went soft. A week later, fancy defense lawyers for poultry executives accused of price-fixing filed a motion to let them strike jurors from the jury pool, alleging that this comment at a conference in Chicago tainted the jury pool in Colorado. They argued that \u201cputting aside the crass double-entendre, the comment is designed to bolster public approval for aggressive criminal prosecution.\u201d Apparently, they imagine, that\u2019s a no no. More here. There\u2019s a lot of yelling about oil and gas prices, but in California, researcher Severin Borenstein has identified something called the \u2018mystery gasoline surcharge,\u2019 which is the \u201cunexplained difference between California retail gasoline prices and the rest of the country, after adjusting for taxes and environmental fees.\u201d This amount is about 40 cents a gallon, or $4 billion a year. The reason? Refining consolidation, and downstream control by those refiners. Here\u2019s Borenstein. The net effect is a big price differential between major brands and off-brands in California. There aren\u2019t that many things policymakers can do about gas prices. But going after refining consolidation is one of them. Trade Group Driving Solar Controversy Includes Slave-Labor Companies, The American Prospect<br \/> Climbing costs: Soaring inflation tests buyout bosses, Private Equity News<br \/> Antitrust and Architecture: Coordination not Domination, New York Review of Architecture<br \/> Monopolies Killed My Hometown, by Andrew Cameron<br \/> The AMA\u2019s Little-Known Committee that Sets Physician Service Prices, Washington Monthly<br \/> Maritime Software Consolidation: Veson Nautical Acquires Q88, gCaptain<br \/> Break up Live Nation over lax safety record including Astroworld tragedy, Chappelle show: NJ pol, New York Post<br \/> Facebook Deliberately Caused Havoc in Australia to Influence New Law, Whistleblowers Say, Wall Street Journal. American Importers Accuse Shipping Giants of Profiteering, New York Times<br \/> Don\u2019t Call Tony Fadell an Asshole\u2014He Prefers \u2018Mission Driven\u2019, Wired. This interview is important, because it shows why entrepreneurs often sell out to big tech. It\u2019s not efficiency, it\u2019s fear. Fadell sold his company Nest, which Google sort of ruined, yet he thinks it was \u201cthe right decision\u201d to let Google buy his creation. Why? \u201cA platform requires tons of capital and tons of time to build. And if anybody showed up who already had a platform, we&#8217;d be screwed. You know what happened to Palm. I&#8217;d watched this play before.\u201d Mergers are usually not, shall we say, efficient. Thanks for reading! And please send me tips on weird monopolies, stories I\u2019ve missed, or comments by clicking on the title of this newsletter. And if you liked this issue of BIG, you can sign up here for more issues, a newsletter on how to restore fair commerce, innovation and democracy. And consider becoming a paying subscriber to support this work, or if you are a paying subscriber, giving a gift subscription to a friend, colleague, or family member.<br \/>cheers,<br \/> Matt Stoller<br \/>&#8222;There are two basic mechanisms that have created a concentrated and brittle market. The first is that regulators. And the second is that the Federal government.&#8220; It seems like virtually all of your articles contain some variation of this to explain why things are such a mess. Here&#8217;s an oversimplified, but likely means through which baby formula can have detectable levels of arsenic: Some formulas are made with a lot of rice. Apparently, rice starch seems to be used as a thickener or means to reduce incidents of babies spitting up, at least according to Enfamil&#8217;s own product description on Amazon. Rice tends to have measurable amounts of arsenic based on how and where it&#8217;s grown. Per one NIH study, rice grown in the South and Central US (old cotton land) has nearly twice the arsenic as Californian rice. Just use your favorite search engine with the terms rice, arsenic, southern US. Home scale cooking can mitigate arsenic levels by thoroughly washing rice grains and wasting a whole lot of water (this also removes almost all enrichment via factory sprayed on nutrients). Something tells me baby formula makers work to use as little water as possible while preserving as much grain\/starch\/nutrient content as possible. This would encourage the retention of any arsenic present.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is a true crisis that is a long-time coming. Thank the baby formula monopoly, its partner at the Food and Drug Administration, and the Department of Agriculture. Welcome to BIG, a newsletter about the politics of monopoly. If you\u2019d like to sign up, you can do so here. Or just read on\u2026 Today I\u2019m [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2172066,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[113],"tags":[],"_links":{"self":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts\/2172067"}],"collection":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/comments?post=2172067"}],"version-history":[{"count":0,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts\/2172067\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/media\/2172066"}],"wp:attachment":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/media?parent=2172067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/categories?post=2172067"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/tags?post=2172067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}